Signal transduction and oncogenesis by ErbB/HER receptors

Marmor, Mina D; Skaria, Kochupurakkal Bose; Yarden, Yosef

doi:10.1016/j.ijrobp.2003.06.002

Cited by 389HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsGastric Cancer Management and Outcomes

Signal transduction and oncogenesis by ErbB/HER receptors

Marmor, Mina D, Skaria, Kochupurakkal Bose, Yarden, Yosef·2004·International Journal of Radiation Oncology*Biology*Physics

DOI 10.1016/j.ijrobp.2003.06.002

Open this paper in CoChat — free account

Abstract

Growth factors enable cells to escape irradiation-induced death (apoptosis). One important family of growth factors share an epidermal growth factor motif, and all bind to ErbB transmembrane receptors. In response to growth factor ligands, ErbB receptor tyrosine kinases induce a variety of cellular responses, including proliferation, differentiation and motility. Signal transduction pathways are initiated upon ligand-induced receptor homo- or heterodimerization and activation of tyrosine kinase activity. The complement of induced signaling pathways, as well as their magnitude and duration, determines the biological outcome of signaling, and in turn, is regulated by the identity of the ligand and the receptor composition. Recent insights into the structural basis for receptor dimerization, as provided by crystallographic analysis, are described, as is the differential activation of signaling pathways and downregulatory mechanisms. Further, dysregulation of the ErbB network is implicated in a variety of human cancers, and the nature of aberrant signaling through ErbB proteins, as well as current therapeutic approaches, are discussed, highlighting the role of the highly oncogenic ErbB-2 molecule.

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2003.06.002

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

EGFR still plays a role in activation of other key pathways such as PI3K/AKT, STATs, and PLCγ/PKC.
“the EGFR still plays a role in the activation of other key pathways such as the PI3K/AKT pathway, STATs pathway and the PLCγ/PKC pathways (Marmor et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Marmor et al., 2004
EGFR couples growth factor signaling to the RAS/RAF/MEK/ERK pathway.
“the EGFR couples growth factor signaling to the RAS/RAF/MEK/ERK pathway”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Marmor et al., 2004
Mutations in KRAS uncouple the RAS/RAF/MEK/ERK pathway from EGFR.
“mutations in KRAS uncouple this pathway from the receptor”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Marmor et al., 2004

Oncogenic kinase signalling.
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · see citing works
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Skeletal muscle stem cells express anti-apoptotic ErbB receptors during activation from quiescence.
Golding, J. P., Calderbank, E. F., Partridge, T. A., & Beauchamp, J. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.10.019 · Cited by 801 · see citing works
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works
Regulation of Raf-1 by direct feedback phosphorylation.
Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663 · see citing works
“…of upstream3 Department of Medicine regulators of Raf-1, such as receptor tyrosine kinasesBeth Israel Deaconess Medical Center (Holbro et al., 2003; Marmor et al., 2004) and Ras (Bos,Harvard Medical School 1989; Pruitt and Der, 2001), frequently induces deregu-Boston, Massachusetts 02215 lated…”
Background
The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions
Keshet, Y., & Seger, R. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-795-2_1 · Cited by 642 · see citing works
The ERK Cascade: Distinct Functions within Various Subcellular Organelles
Wortzel, I., & Seger, R. (2011) · Genes & Cancer · doi:10.1177/1947601911407328 · Cited by 563 · see citing works
Identification of genes that regulate epithelial cell migration using an siRNA screening approach
Simpson, K., Selfors, L., Bui, J., Reynolds, A., Leake, D., Khvorova, A., & Brugge, J. (2008) · Nature Cell Biology · doi:10.1038/ncb1762 · Cited by 448 · see citing works
“ERBB2 has strong pro-survival activity and allows EGF-independent proliferation of MCF-10A cell”
Background
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling
Mason, J. M., Morrison, D. J., Basson, M. A., & Licht, J. D. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.11.004 · Cited by 426 · see citing works
Cell surface-associated mucins in signal transduction.
Singh, P., & Hollingsworth, M. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.07.006 · Cited by 434 · see citing works
ErbB Receptors and Cancer
Wang, Z. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 436 · see citing works
Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi, Y., Yasui, H., Kakudo, K., & Nozaki, M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3215 · Cited by 283 · see citing works
“These pathways affect various cellular responses, including proliferation, survival, migration, angiogenesis and metastasis (4-10).”
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
Faivre, S. J., Djelloul, S., & Raymond, É. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 270 · see citing works
The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases
Laederich, M. B., Funes, M., Yen, L., Ingalla, E. Q., Wu, X., Carraway, K. L., & Sweeney, C. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409703200 · Cited by 236 · see citing works
Nuclear EGFR as a Molecular Target in Cancer
Brand, T. M., Iida, M., Luthar, N., Starr, M. M., Huppert, E. J., & Wheeler, D. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.010 · Cited by 238 · see citing works
“Ligand binding causes a conformational change in the receptor that allows for both homo- and hetero-dimerization with other activated HER family members [3].”
Background
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer
Lafky, J. M., Wilken, J. A., Baron, A. T., & Maihle, N. J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.01.001 · Cited by 215 · see citing works
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
Elkind, N. B., Szentpétery, Z., Apáti, Á., Özvegy‐Laczka, C., Várady, G., Ujhelly, O., Szabó, K., Homolya, L., Váradi, A., Buday, L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3303 · Cited by 223 · see citing works
“The epidermal growth factor receptor (EGFR) signaling pathway regulates diverse physiologic responses, including proliferation, differentiation, cell motility, and survival ( 1 ).”
Background
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
Roepstorff, K., Grøvdal, L. M., Grandal, M. M., Lerdrup, M., & van Deurs, B. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0401-3 · Cited by 200 · see citing works
“ErbB2 is one of the most prominent client proteins of the chaperone HSP90 (Citri and Yarden 2006; Linggi and Carpenter 2006), and this interaction is considered as a potentially valuable pharmacological target (Citri et al. 2004; Marmor et al. 2004; Neckers 2002; Neckers and Ivy 2003).”
Background
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells
Vázquez-Martín, A., Colomer, R., Brunet, J., Lupu, R., & Menendez, J. A. (2008) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00498.x · Cited by 216 · see citing works
“Because the process of malignant transformation in many cancers may depend on the abnormal activation of ligands, receptors and signal transduction cascades that function as part of the HER-(Tyr-kinase) axis (Olayioye 2001; Yarden & Sliwkowski 2001; Gross et al. 2004; Marmor et al. 2004; Citri &”
Background
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214 · see citing works
The ERK Cascade: A Prototype of MAPK Signaling
Rubinfeld, H., & Seger, R. (2005) · Molecular Biotechnology · doi:10.1385/mb:31:2:151 · Cited by 460 · see citing works
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier, S., Horvath, G. L., Knuechel-Clarke, R., Hofstaedter, F., Szöllősi, J., & Brockhoff, G. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.008 · Cited by 192 · see citing works
Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
Baumann, M. A., & Krause, M. (2004) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.07.007 · Cited by 177 · see citing works
Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells.
Cowden-Dahl, K., Symowicz, J., Ning, Y., Gutierrez, E. T., Fishman, D., Adley, B., Stack, M., & Hudson, L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5046 · Cited by 182 · see citing works
Histological evaluation of AMPK signalling in primary breast cancer
Hadad, S. M., Baker, L., Quinlan, P., Robertson, K. E., Bray, S. E., Thomson, G., Kellock, D., Jordan, L. B., Purdie, C. A., Hardie, D. G., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-307 · Cited by 172 · see citing works
“FAS is up-regulated in about 50% of breast cancers, is an indicator of poor prognosis, and is associated with the HER2 oncogene [22-24].”
Background
Oncogenes in Cell Survival and Cell DeathPreprint
Shortt, J., & Johnstone, R. W. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009829 · Cited by 195 · see citing works
“EGFR activation results in an explosion of intracellular signaling including triggering of the RAS/RAF/ MEK/ERK and PI3K/AKT/MTOR pathways, as well as activation of Src tyrosine kinases, PLCg, and STATs 3 and 5 (Marmor et al. 2004).”
Background
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
Wen, X.-F., Yang, G. S., Mao, W., Thornton, A., Liu, J., Bast, R. C., & Le, X.-F. (2006) · Oncogene · doi:10.1038/sj.onc.1209685 · Cited by 159 · see citing works
“The human epidermal growth factor receptor 2 (HER2, also known as ErbB-2 or c-neu) plays a critical role in epidermal growth factor receptor (EGFR) family signaling (Zhang et al., 2003; Holbro and Hynes, 2004; Marmor et al., 2004).”
Background
Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
Menéndez, J. A., Vellón, L., & Lupu, R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi239 · Cited by 180 · see citing works
“As a part of our efforts to assess the role of FAS signaling on the survival and proliferation of breast cancer cells, we recently identified a novel bi-directional molecular linkage between breast cancer-associated FAS activity and Her2/neu (erbB-2), a well-characterized oncogene that is overexpressed in about 30% of…”
Background
Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells
Liu, X.-S., Huang, J., Chen, T.-T., Wang, Y., Xin, S., Li, J., Pei, G., & Kang, J.-H. (2008) · Cell Research · doi:10.1038/cr.2008.309 · Cited by 158 · see citing works
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 141 · see citing works
“The two main functions d stability and enhancing cell proliferation [80] and translocation an transducer and activator of transcription (STATs) activation have also been documented [8].”
Background
A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2*
Sidera, K., Gaitanou, M., Stellas, D., Matsas, R., & Patsavoudi, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m701803200 · Cited by 156 · see citing works
The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.
Żaczek, A., Brandt, B. H., & Bielawski, K. (2005) · Histology and Histopathology · doi:10.14670/hh-20.1005 · Cited by 156 · see citing works
Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives
Menéndez, J. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.005 · Cited by 157 · see citing works
On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model
Orlova, A., Wållberg, H., Stone-Elander, S., & Tolmachev, V. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057919 · Cited by 152 · see citing works
“Different approaches for the treatment of tumors that overexpress the HER family proteins are currently available (1).”
Background
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133 · see citing works
“Collectively, these pathways influence several cellular responses, including cell proliferation, survival, migration, angiogenesis and metastasis (reviewed in Biscardi et al., 1999b; Abram and Courtneidge, 2000; Schlessinger, 2000; Blume-Jensen and Hunter, 2001; Prenzel et al., 2001; Yarden and Sliwkowski, 2001; Marmo…”
BackgroundInfluential
Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
Siddiqa, A., Long, L., Li, L.-X., Marciniak, R. A., & Kazhdan, I. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-129 · Cited by 130 · see citing works
“Over-expression of HER-2 has been reported to activate multiple signal transduction pathways including RasMAPK, the PI3-K-Akt-NF-kappaB cascade and STAT 3 [24].”
Background
A combined oncogenic pathway signature of BRAF , KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
Tian, S., Simon, I., Moreno, V., Roepman, P., Tabernero, J., Snel, M., van't Veer, L., Salazar, R., Bernards, R., & Capella, G. (2013) · Gut · doi:10.1136/gutjnl-2012-302423 · Cited by 128 · see citing works
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
Ghayad, S., Vendrell, J., Larbi, S. B., Dumontet, C., Bièche, I., & Cohen, P. (2010) · International Journal of Cancer · doi:10.1002/ijc.24750 · Cited by 127 · see citing works
“and/or heterodimerization of the ErbB receptors and compelling data suggest that the different homo- or heterodimers can have distinct functions.(70) The oncogenic function of ErbB2 has been shown to require ErbB3.”
The emerging role of the PI3-K-Akt pathway in prostate cancer progression
Li, L., Ittmann, M., Ayala, G., Tsai, M., Amato, R. J., Wheeler, T. M., Miles, B. J., Kadmon, D., & Thompson, T. C. (2005) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500776 · Cited by 120 · see citing works
Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology
Huang, J.-H., Cheung, F., Tan, H.-Y., Hong, M., Wang, N., Yang, J., Feng, Y.-B., & Zheng, Q. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7149 · Cited by 125
“Pathway enrichment analyses demonstrated YCHD to be involved with regulation of multiple pathways in cancer, including apoptosis (1) as well as various signaling pathways: NOD‑like receptor (42), Toll‑like receptor (43), Fc epsilon RI (44), B-cell receptor (45), ErbB (46), VEGF (47), and GnRH (48).”
The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining
Kriegs, M., Kasten-Pisula, U., Rieckmann, T., Holst, K., Saker, J., Dahm‐Daphi, J., & Dikomey, E. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.05.005 · Cited by 118 · see citing works
VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase
Wright, G. L., Maroulakou, I. G., Eldridge, J. D., Liby, T. L., Sridharan, V., Tsichlis, P. N., & Muise‐Helmericks, R. C. (2008) · The FASEB Journal · doi:10.1096/fj.08-106468 · Cited by 133 · see citing works
High- and Low-Affinity Epidermal Growth Factor Receptor-Ligand Interactions Activate Distinct Signaling Pathways
Krall, J. A., Beyer, E., & MacBeath, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015945 · Cited by 120 · see citing works
“ylation [2], initiating a wide variety of signaling cascades including the Ras/MAPK, PI3K/Akt, PLCc/PKC, and Stat pathways [3].”
Background
Retinoid-Induced Epidermal Hyperplasia Is Mediated by Epidermal Growth Factor Receptor Activation Via Specific Induction of its Ligands Heparin-Binding EGF and Amphiregulin in Human Skin In Vivo
Rittié, L., Varani, J., Kang, S., Voorhees, J. J., & Fisher, G. J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700202 · Cited by 114 · see citing works
Expression of zonula occludens‐1 (ZO‐1) and the transcription factor ZO‐1‐associated nucleic acid‐binding protein (ZONAB)–MsY3 in glial cells and colocalization at oligodendrocyte and astrocyte gap junctions in mouse brain
Penes, M., Li, X. (., & Nagy, J. I. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04225.x · Cited by 115 · see citing works
“Neu or HER2), which has diverse roles in regulation of cell growth and differentiation (Casalini et al., 2004; Holbro & Hynes, 2004; Marmor et al., 2004).”
Background
Reaching out for signals
Lidke, D. S., Lidke, K. A., Rieger, B., Jovin, T. M., & Arndt‐Jovin, D. J. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200503140 · Cited by 229 · see citing works
Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling.
Hwang, Y., Yun, H., Choi, J. H., Han, E., Kim, H. G., Song, G. Y., Kwon, K., Jeong, T., & Jeong, H. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201000292 · Cited by 110 · see citing works
Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis
Yu, G.-H., Wang, W., Wang, X., Xu, M., Zhang, L.-L., Ding, L., Guo, R., & Shi, Y. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2356-9 · Cited by 108 · see citing works
The status and role of ErbB receptors in human cancer.
Uberall, I., Kolář, Z., Trojanec, R., Berkovcová, J., & Hajduch, M. (2008) · Experimental and molecular pathology (Print) · doi:10.1016/j.yexmp.2007.12.002 · Cited by 101 · see citing works
Cyclic AMP synergistically enhances neuregulin‐dependent ERK and Akt activation and cell cycle progression in Schwann cells
Monje, P., Bunge, M. B., & Wood, P. M. (2006) · Glia · doi:10.1002/glia.20330 · Cited by 98 · see citing works
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
Mimura, K., Shiraishi, K., Mueller, A., Izawa, S., Kua, L., So, J., Yong, W., Fujii, H., Seliger, B., Kiessling, R., et al. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1301597 · Cited by 92 · see citing works
“In the current study, we examined the relationship between the HER2-signaling pathway (MAPK and PI3K-Akt) and the expression of HLA class I and Ag-processing machinery (APM) components.”
BackgroundInfluential
MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer.
Zhao, D., Sui, Y.-X., & Zheng, X.-Q. (2016) · Oncology Report · doi:10.3892/or.2015.4450 · Cited by 89
“HER2 is an important regulator of EGFR family signaling (21,22).”
Background
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Dempke, W. C. M., & Heinemann, V. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.038 · Cited by 80 · see citing works
“Through Akt activation, EGF-R induces Bad phosphorylation, thereby inhibiting its proapoptotic interaction with Bcl-2 and Bcl-x.(58) Functional inactivation of PTEN (often loss of 1 allele followed by mutation in the other) has been observed in several human cancers.”
Background
Extracellular HSP90: Conquering the cell surface
Sidera, K., & Patsavoudi, E. (2008) · Cell Cycle · doi:10.4161/cc.7.11.6054 · Cited by 88 · see citing works
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Tu, L., de Man, F. S., Girerd, B., Huertas, A., Chaumais, M., Lecerf, F., François, C., Perros, F., Dorfmüller, P., Fadel, E., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0309oc · Cited by 87 · see citing works
Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways.
Carraway, K., Funes, M., Workman, H. C., & Sweeney, C. (2007) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)78001-2 · Cited by 87 · see citing works
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.
Gurtner, K., Deuse, Y., Bütof, R., Schaal, K., Eicheler, W., Oertel, R., Grénman, R., Thames, H., Yaromina, A., Baumann, M., et al. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.035 · Cited by 86 · see citing works
An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
Li, H.-W., Yu, C., Jiang, J., Huang, C.-J., Yao, X.-J., Xu, Q.-Y., Yu, F., Lou, L., & Fang, J.-M. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139248 · Cited by 85
Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance
Sahin, Ö., Fröhlich, H., Loebke, C., Korf, U., Burmester, S., Majety, M., Mattern, J., Schupp, I., Chaouiya, C., Thieffry, D., et al. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-1 · Cited by 85 · see citing works
“The ERBB family of receptor tyrosine kinases is composed of four receptors that have the ability to form homo- and heterodimers, and couple binding of extracellular growth factors to intracellular signal transduction pathways [3,4].”
Background
Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
Iida, M., Brand, T. M., Campbell, D., Li, C.-R., & Wheeler, D. (2012) · Oncogene · doi:10.1038/onc.2012.90 · Cited by 84 · see citing works
“The phosphorylated cytoplasmic tail of the EGFR serves as docking sites for numerous proteins that initiates key oncogenic pathways including the RAS/RAF/MEK/ERK and phosphatidylinositol 3-kinase (PI3K)-Akt pathways; however, the activation of src family tyrosine kinases (SFKs), Phospholipase C-gamma (PLC), Protein ki…”
Background
Nanoparticles for biomedical applications: exploring and exploiting molecular interactions at the nano-bio interface
Nienhaus, K., Wang, H., & Nienhaus, G. U. (2020) · Materials Today Advances · doi:10.1016/j.mtadv.2019.100036 · Cited by 106 · see citing works
“types of cancer, including an aggressive form of breast cancer [181].”
Background
Whole genome DNA methylation signature of HER2-positive breast cancer
Lindqvist, B. M., Wingren, S., Motlagh, P. B., & Nilsson, T. (2014) · Epigenetics · doi:10.4161/epi.29632 · Cited by 81 · see citing works
“HER receptors, when activated, dimerize and activate the downstream signaling through multiple pathways, including phosphotidylinositol 3-kinase (PI3K)-activated protein kinase B (AKT) pathway, resulting in induction of cell cycle progression/survival, inhibition of apoptosis, promotion of angiogenesis, and invasion.(…”
Background
Genetic dissection of growth traits in a Chinese indigenous × commercial broiler chicken cross
Sheng, Z.-Y., Pettersson, M. E., Hu, X.-X., Luo, C., Qu, H., Shu, D., Shen, X., Carlborg, Ö., & Li, N. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-151 · Cited by 81
“…QTL pairs affecting FCR 6 – 8 and FCR 8 – 10, we also found possible interacting candidate genes in a growth-related pathway, the ErbB signalling pathway, which is known to affect intra-cellular signalling pathways regulating cell proliferation, differentiation, cell motility, and survival [23].”
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Inoue, M., Mimura, K., Izawa, S., Shiraishi, K., Inoue, A., Shiba, S., Watanabe, M., Maruyama, T., Kawaguchi, Y., Inoue, S., et al. (2012) · Oncoimmunology · doi:10.4161/onci.21056 · Cited by 80 · see citing works
Signal Transduction in Early Heart Development (II): Ventricular Chamber Specification, Trabeculation, and Heart Valve Formation
Wagner, M., & Siddiqui, M. (2007) · Experimental biology and medicine · doi:10.3181/00379727-232-2320866 · Cited by 80
“In the case of ErbB signaling, this could be any or all of four different signal transduction pathways: the Ras-mitogen– activated protein kinase (Ras-MAPK) pathway, the phophatidylinositol 39 kinase–protein kinase B (PI3K-PKB/ Akt) pathway, the phospholipase C–protein kinase C (PLCPKC) pathway, or the Jak/STAT pathwa…”
Background
Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.
Rittié, L., Kansra, S., Stoll, S., Li, Y., Gudjonsson, J., Shao, Y., Michael, L. E., Fisher, G., Johnson, T., & Elder, J. T. (2007) · American Journal of Pathology · doi:10.2353/ajpath.2007.060537 · Cited by 79 · see citing works
Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms
Sei, Y., Ren‐Patterson, R. F., Li, Z., Tunbridge, E. M., Egan, M. F., Kolachana, B. S., & Weinberger, D. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001994 · Cited by 76 · see citing works
Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
Krause, M., Schütze, C., Petersen, C., Pimentel, N., Hessel, F., Harstrick, A., & Baumann, M. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.10.011 · Cited by 79
“Via phosphorylation of the intracellular tyrosine kinase, the downstream pathways result in proliferation of tumour cells and in increased radioresistance [13,18,19,22].”
Background
Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells.
Cheng, J.-C., Klausen, C., & Leung, P. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0034 · Cited by 78 · see citing works
Stepwise movements in vesicle transport of HER2 by motor proteins in living cells.
Watanabe, T. M., & Higuchi, H. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.094649 · Cited by 78 · see citing works
“setup because HER2 does not have a ligand binding step (36,37).”
Background
System-Wide Investigation of ErbB4 Reveals 19 Sites of Tyr Phosphorylation that Are Unusually Selective in their Recruitment Properties
Kaushansky, A., Gordus, A., Budnik, B., Lane, W. A. S., Rush, J., & MacBeath, G. (2008) · Chemistry and Biology · doi:10.1016/j.chembiol.2008.07.006 · Cited by 76 · see citing works
“, 1998; Yarden and Sliwkowski, 2001) and ErbB2 does not recognize an extracellular ligand (Marmor et al., 2004; Yarden and Sliwkowski, 2001).”
Background
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 72 · see citing works
“Heterodimerizaion of ErbBs results in phosphotyrosine residues additional to hose in homodimers and enables the recruitment of binding artners that yield more potent mitogenic signals [9].”
Background
Signal Transduction in Early Heart Development (I): Cardiogenic Induction and Heart Tube Formation
Wagner, M., & Siddiqui, M. (2007) · Experimental biology and medicine · doi:10.3181/00379727-232-2320852 · Cited by 75
Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells.
Cheng, J.-C., Klausen, C., & Leung, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.10.029 · Cited by 73 · see citing works
“64 Accumulating evidence suggests a role for EGF/EGF receptor signaling in tumor 65 metastasis [23-25].”
Transmembrane helix-helix interactions involved in ErbB receptor signaling
Cymer, F., & Schneider, D. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.2.11191 · Cited by 73 · see citing works
Signaling through ShcA Is Required for Transforming Growth Factor β- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion
Northey, J. J., Chmielecki, J., Ngan, E., Russo, C., Annis, M., Muller, W., & Siegel, P. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01734-07 · Cited by 73 · see citing works
“These include Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain-containing proteins such as PLC 1, Src, Ras-GAP, Grb-2, Grb-7, and ShcA, among others (30).”
Background
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Pieve, C. D., Allott, L., Martins, C. D., Vardon, A., Ciobota, D. M., Krämer-Marek, G., & Smith, G. S. T. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00259 · Cited by 75 · see citing works
An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris
Pretel, M., España, A., Marquina, M., Pelacho, B., López-Picazo, J. M., & López-Zabalza, M. J. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00893.x · Cited by 70 · see citing works
Pertuzumab and trastuzumab: the rationale way to synergy.
Richard, S., Selle, F., Lotz, J., Khalil, A., Gligorov, J., & Soares, D. G. (2016) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201620150178 · Cited by 71 · see citing works
ErbB receptors in the biology and pathology of the aerodigestive tract
Morgan, S., & Grandis, J. R. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.08.009 · Cited by 67 · see citing works
“This is caused by an increased ligand affinity through a decelerated rate of ligand dissociation, efficient coupling to signaling pathways and a decreased rate of receptor downregulation through endocytosis [101].”
Background
Identification of Nucleolin as New ErbB Receptors- Interacting Protein
Segni, A. D., Farin, K., & Pinkas-Kramarski, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002310 · Cited by 66 · see citing works
“As overexpression of ErbB receptors is often found in several human tumors such as breast, lung, head, and neck [24], their precise role in the cell is of particular biological and pharmacological importance.”
Background
Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region.
Spindler, K., Nielsen, J., Lindebjerg, J., Brandslund, I., & Jakobsen, A. (2006) · International Journal of Radiation Oncology, Biology, Physics · doi:10.1016/j.ijrobp.2006.03.030 · Cited by 66
An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib
Kuruppu, A., Zhang, L., Collins, H., Turyanska, L., Thomas, N. R., & Bradshaw, T. D. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500389 · Cited by 64
Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
Wagner, J. P., Wolf‐Yadlin, A., Sevecka, M., Grenier, J. K., Root, D. E., Lauffenburger, D. A., & MacBeath, G. (2013) · Science Signaling · doi:10.1126/scisignal.2003994 · Cited by 66 · see citing works
“The targeted proteins function in various pathways downstream of RTKs, notably the phosphatidylinositol 3-kinase (PI3K) to Akt pathway, the Ras to MAPK (mitogen-activated protein kinase) pathway, and the phospholipase C–γ (PLC-γ) to protein kinase C (PKC) or Ca2+ signaling pathway (15).”
Background
EGFR/HER-Targeted Therapeutics In Ovarian Cancer
Wilken, J. A., Badri, T., Cross, S., Raji, R., Santin, A. D., Schwartz, P. E., Branscum, A. J., Baron, A. T., Sakhitab, A. I., & Maihle, N. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.11 · Cited by 60 · see citing works
Cetuximab and Doxorubicin loaded dextran-coated Fe3O4 magnetic nanoparticles as novel targeted nanocarriers for non-small cell lung cancer
Zhang, Q., Liu, Q., Du, M., Vermorken, A., Cui, Y.-L., Zhang, L., Guo, L., Ma, L., & Chen, M.-W. (2019) · Journal of Magnetism and Magnetic Materials · doi:10.1016/j.jmmm.2019.01.021 · Cited by 61
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules
Tolmachev, V., Mume, E., Sjöberg, S., Frejd, F., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1003-y · Cited by 61 · see citing works
“Overexpression of HER2 in breast cancer is associated with a poor prognosis [4] and its involvement in malignant transformation of cancer cells makes it a promising target for a therapy [5].”
Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?
Glynne-Jones, R., & Hoskin, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3133 · Cited by 61 · see citing works
Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma
Schütze, C., Dörfler, A., Eicheler, W., Zips, D., Hering, S., Solca, F., Baumann, M., & Krause, M. (2007) · Strahlentherapie und Onkologie (Print) · doi:10.1007/s00066-007-1696-z · Cited by 61
“The ErbB2 receptor is the preferred and most potent heterodimerization partner for other EGFR/ErbB family members [14, 25, 44].”
Background
T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2
Mimura, K., Ando, T., Poschke, I., Mougiakakos, D., Johansson, C. C., Ichikawa, J., Okita, R., Nishimura, M., Handke, D., Krug, N., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25613 · Cited by 60 · see citing works
“Over-expression of HER2 has been reported to activate multiple signaling pathways including the PI3-K-Akt-NF-kappaB cascade, Ras-MAPK and STAT3.”
Background
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest
Kriegs, M., Gurtner, K., Can, Y., Brammer, I., Rieckmann, T., Oertel, R., Wysocki, M., Dorniok, F., Gal, A., Grob, T. J., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.018 · Cited by 58 · see citing works
Alteration of gene expression profiles during mycoplasma-induced malignant cell transformation
Zhang, S.-M., Tsai, S.-E., & Lo, S.-C. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-116 · Cited by 59 · see citing works
“Over-expression or down-regulation of a single molecule that plays an important role in the control of cell proliferation could evidently alter the balance of the entire cell physiological network and lead to malignant transformation [27,28].”
Background
Mechanisms of ErbB receptor negative regulation and relevance in cancer
Fry, W., Kotelawala, L., Sweeney, C. A., & Carraway, K. L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.022 · Cited by 45 · see citing works
“Depending upon the specific activating ligand and ErbB dimer combination, ErbB dimers can stimulate a wide variety of cellular signaling pathways that culminate in the nucleus to drive transcriptional programs controlling cell migration, survival, adhesion, differentiation, and proliferation (7).”
Background
Differentiation of human airway epithelia is dependent on erbB2.
Vermeer, P., Panko, L., Karp, P. H., Lee, J. H., & Zabner, J. (2006) · American Journal of Physiology - Lung cellular and Molecular Physiology · doi:10.1152/ajplung.00547.2005 · Cited by 57 · see citing works
“Human lung fibroblasts express TGF- , HB-EGF, epiregulin, heregulin- , and amphiregulin, all erbB ligands (16) (Fig.”
Background
RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation
Azmi, P., & Seth, A. K. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.020 · Cited by 56 · see citing works
Roles for neuregulins in human cancer
Stove, C., & Bracke, M. (2005) · Clinical and Experimental Metastasis · doi:10.1007/s10585-004-6917-6 · Cited by 57 · see citing works
“have been reviewed recently and will not be discussed into detail here [55, 58, 59].”
Background
Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule
Orlova, A., Malm, M., Rosestedt, M., Varasteh, Z., Andersson, K. G., Selvaraju, R., Altai, M., Honarvar, H., Strand, J., Ståhl, S., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2733-7 · Cited by 56 · see citing works
“It has also been shown that the deregulation of HER family expression and signaling is associated with malignant transformation and tumor progression [2].”
Background
Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
Hervent, A.-S., & Keulenaer, G. D. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012268 · Cited by 56 · see citing works
“As overexpression of EGFR and ErbB2 receptors is often found in several human tumours such as breast, lung, head, and neck [11], ErbB receptors have been intensely pursued as therapeutic targets [8].”
Background
Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells
Buvinic, S., Bravo‐Zehnder, M., Boyer, J., Huidobro-Toro, J., & González, A. (2007) · Journal of Cell Science · doi:10.1242/jcs.03490 · Cited by 56 · see citing works
“Activated EGFR conveys mitogenic signals mainly through the Ras-RafMEK-MAPK pathway (Marmor et al., 2004; Schlessinger, 2002).”
Background
PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor–Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells
Cowden-Dahl, K., Zeineldin, R., & Hudson, L. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0019 · Cited by 56 · see citing works
“Cellular responses to EGFR activation include those that play a critical role in tumor growth, survival, and progression, whereas EGFR overexpression in tumors has been associated clinically with progression and metastasis (9-11).”
Background
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
Wang, Y., Kristensen, G., Helland, Å., Nesland, J., Børresen-Dale, A., & Holm, R. (2005) · American Journal of Clinical Pathology · doi:10.1309/bl7emw66lqx6gfrp · Cited by 56
Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors
Ngaha, T. Y. S., Zhilenkova, A., Essogmo, F. E., Uchendu, I., Abah, M., Fossa, L., Sangadzhieva, Z. D., Sanikovich, V., Rusanov, A. S., Pirogova, Y. N., et al. (2023) · Cancers · doi:10.3390/cancers15184648 · Cited by 55 · see citing works
“in many cancers and increase angiogenesis by activating both the PI3K/Akt and MAPK/ERK signaling pathways [118].”
Background

Authors: Marmor, M. D., Skaria, K. B., & Yarden, Y.
Affiliations: Weizmann Institute of Science (IL)
Corresponding author: Yarden, Yosef
ORCID: Yarden, Yosef
Venue: International Journal of Radiation Oncology*Biology*Physics
Publisher: Elsevier BV
Published: 2004-03
Volume: 58
Issue: 3
Pages: 903-913
ISSN: 0360-3016 (ISSN-L)
DOI: 10.1016/j.ijrobp.2003.06.002
OpenAlex: W2131361386
Cited by: 389
References: 141
Citations by year: 2026: 6 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 3 · 2020: 15 · 2019: 13 · 2018: 10 · 2017: 14 · 2016: 14 · 2015: 18 · 2014: 18 · 2013: 24 · 2012: 27
FWCI: 3.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: International Journal of Radiation Oncology*Biology*Physics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
Keywords: ErbB receptors, receptor tyrosine kinase, signal transduction, carcinogenesis, receptor dimerization, tyrosine kinase activation, growth factor signaling, apoptosis, receptor down-regulation, ERBB2, HER2, cancer therapy, radiation-induced cell death
MeSH terms: Antibodies, Monoclonal, Enzyme Activation, Ligands, Neoplasms, Type C Phospholipases, Protein Kinase C, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Structure-Activity Relationship, Signal Transduction, Down-Regulation, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Dimerization, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins c-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Signal transduction and oncogenesis by ErbB/HER receptors

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Record

About these checks